Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna
, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Don Healey, Ph.D., Opexa’s Chief Scientific Officer, has been invited as a guest speaker to participate in the Phacilitate Cell & Gene Therapy Forum. The event will take place January 27-29, 2014, at The Grand Hyatt in Washington, DC.
Dr. Healey will discuss the design and value of potency assays to render them more relevant to cell and gene therapy and more appropriate to clinical practice/benefit, during the focus session, "
Process Standardization and Comparability - Do We Need a Rethink?
Dr. Healey's presentation, entitled, "
Individual Lots of Autologous Product, All the Same but Different: The Potency Conundrum"
will take place on Monday, January 27th at 12pm EST.
The Phacilitate Cell & Gene Therapy Forum is the preeminent industry led meeting place pushing the maturation of regulatory, manufacturing, R&D and commercial strategies.
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna
, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of SPMS. Tcelna is derived from T-cells isolated from a patient’s peripheral blood, expanded ex vivo, and reintroduced into the patient via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.
About Multiple Sclerosis (MS)
MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.
While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The secondary progressive form of MS represents about a third of the MS patient population.